Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
- 5 May 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (3), 505-508
- https://doi.org/10.1002/pbc.21988
Abstract
Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2‐log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers. Pediatr Blood Cancer 2009;53:505–508.Funding Information
- National Cancer Institute (NO1-CM-42216, CA21765, CA108786)
This publication has 20 references indexed in Scilit:
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPediatric Blood & Cancer, 2007
- HDAC inhibitors: Clinical update and mechanism-based potentialBiochemical Pharmacology, 2007
- Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by DepsipeptideJNCI Journal of the National Cancer Institute, 2007
- Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphomaExpert Opinion on Investigational Drugs, 2007
- Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell LymphomaClinical Cancer Research, 2007
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effectNature Medicine, 2003
- Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylationProceedings of the National Academy of Sciences of the United States of America, 2000
- Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastomaNature, 1985